Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NHS Blood and Transplant

- PMLiVE

FDA lifts clinical hold on bluebird bio’s LentiGlobin studies

Company previously put trials on hold after suspected unexpected serious adverse reactions

- PMLiVE

First NHS patient treated with Novartis’ SMA gene therapy Zolgensma

Novartis and NHS England reached a landmark deal for the gene therapy earlier this year

- PMLiVE

Wilmington Healthcare appoints new Solutions Director

Kirsty Fryer has been promoted to the role of Solutions Director for Wilmington Healthcare

Wilmington Healthcare

- PMLiVE

NICE recommends Ultomiris for NHS use in patients with rare blood disorders

aHUS is an ultra-rare and life-threatening disease that causes progressive injury to vital organs

Understanding the role of provider collaboratives

Oli Hudson, Content Director at Wilmington Healthcare, takes a look at the new groups of providers that are expected to play a pivotal role in integrating care.

Wilmington Healthcare

- PMLiVE

FDA approves expanded use for Chiesi’s sickle cell drug Ferriprox

Iron-chelating agent approved for the treatment of transfusional iron overload due to SCD or other anaemias

- PMLiVE

Novartis announces delay in UK cholesterol drug study

The delay was caused by recruitment issues during the COVID-19 pandemic

- PMLiVE

Vertex to lead development of CRISPR Therapeutics-partnered gene therapy

Amended agreement sees Vertex take control of gene therapy programme

- PMLiVE

bluebird bio anticipates lift of clinical holds on LentiGlobin in mid-2021

Previously reported case of MDS in phase 1/2 study has been re-classified as transfusion-dependent anaemia

How does the government plan to reshape the NHS?

Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care

Wilmington Healthcare

- PMLiVE

bluebird bio says AML case “very unlikely” to be related to gene therapy LentiGlobin

bluebird bio's gene therapy LentiGlobin is used to treat sickle cell disease

- PMLiVE

Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA

Children born with SMA type 1 typically have a life expectancy of around two years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links